SEARCH

SEARCH BY CITATION

References

  • Agrawal, B., Krantz, M.J., Reddish, M.A. & Longenecker, B.M. (1998) Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nature Medicine, 4, 4349.
  • Albert, M.L., Sauter, B. & Bhardwaj, N. (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature, 392, 8689.
  • Aluvihare, V.R., Kallikourdis, M. & Betz, A.G. (2004) Regulatory T cells mediate maternal tolerance to the fetus. Nature Immunology, 5, 266271.
  • Andrews, D.M., Scalzo, A.A., Yokoyama, W.M., Smyth, M.J. & Degli-Esposti, M.A. (2003) Functional interactions between dendritic cells and NK cells during viral infection. Nature Immunology, 4, 175181.
  • Asano, M., Toda, M., Sakaguchi, N. & Sakaguchi, S. (1996) Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. Journal of Experimental Medicine, 184, 387396.
  • Austyn, J.M. & Larsen, C.P. (1990) Migration patterns of dendritic leukocytes. Implications for transplantation. Transplantation, 49, 17.
  • Beckhove, P., Witzens, M., Choi, C., Ho, A.D., Goldschmidt, H. & Schirrmacher, V. (2003) MUC1-reactive cytotoxic memory T cells in bone marrow of multiple myeloma patients. Blood, 102, Abstract no. 5227.
  • Bendandi, M., Gocke, C.D., Kobrin, C.B., Benko, F.A., Sternas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., Jaffe, E.S., Creekmore, S.P., Longo, D.L. & Kwak, L.W. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Medicine, 5, 11711177.
  • Bensinger, W., Buckner, C., Anasetti, C., Clift, R., Storb, R., Barnett, T., Chauncey, T., Shulman, H. & Appelbaum, F. (1996) Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood, 88, 27872793.
  • Bjorkstrand, B.B., Ljungman, P., Svensson, H., Hermans, J., Alegre, A., Apperley, J., Blade, J., Carlson, K., Cavo, M., Ferrant, A., Goldstone, A.H., de Laurenzi, A., Majolino, I., Marcus, R., Prentice, H.G., Remes, K., Samson, D., Sureda, A., Verdonck, L.F., Volin, L. & Gahrton, G. (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood, 88, 47114718.
  • Blair, A., Rowbottom, A.W., Browne, S.J., Goulden, N.J., Steward, C.G., Oakhill, A. & Pamphilon, D.H. (2001) An optimised biphasic culture system for the generation of functional dendritic cells from patients with acute lymphoblastic leukaemia at presentation and in clinical remission. Leukemia, 15, 15961603.
  • Bollard, C.M., Savoldo, B., Rooney, C.M. & Heslop, H.E. (2003) Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematologica, 110, 139148.
  • Borrello, I., Biedrzycki, B., Sheets, N., George, B., Racke, F., Loper, K., Noonan, K., Donnelly, A., Hege, K. & Levitski, H.I. (2004) Autologous tumor combined with a GM-CSF-secreting cell line vaccine (GVAX®) following autologous stem cell transplant (ASCT) in multiple myeloma. Blood, 104, Abstract no. 440.
  • Boyer, A., Andreu, G., Romet-Lemonne, J.L., Fridman, W.H. & Teillaud, J.L. (1999) Generation of phagocytic MAK and MAC-DC for therapeutic use: characterization and in vitro functional properties. Experimental Hematology, 27, 751761.
  • Brown, R.D., Yuen, E., Nelson, M., Gibson, J. & Joshua, D. (1997) The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia, 11, 13121317.
  • Brown, R.D., Pope, B., Murray, A., Esdale, W., Sze, D.M., Gibson, J., Ho, P.J., Hart, D. & Joshua, D. (2001) Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood, 98, 29922998.
  • Brown, R., Murray, A., Pope, B., Sze, D.M., Gibson, J., Ho, P.J., Hart, D. & Joshua, D. (2004) Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. British Journal of Haematology, 125, 743748.
  • Campbell, J.D., Cook, G., Robertson, S.E., Fraser, A., Boyd, K.S., Gracie, J.A. & Franklin, I.M. (2001) Suppression of IL-2-induced T cell proliferation and phosphorylation of STAT3 and STAT5 by tumor-derived TGF beta is reversed by IL-15. Journal of Immunology, 167, 553561.
  • Caux, C., Dezutter-Dambuyant, C., Schmitt, D. & Banchereau, J. (1992) GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature, 360, 258261.
  • Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten, C., Durand, I. & Banchereau, J. (1994) Activation of human dendritic cells through CD40 cross-linking. Journal of Experimental Medicine, 180, 12631272.
  • Caux, C., Massacrier, C., Dezutter-Dambuyant, C., Vanbervliet, B., Jacquet, C., Schmitt, D. & Banchereau, J. (1995) Human dendritic Langerhans cells generated in vitro from CD34+ progenitors can prime naive CD4+ T cells and process soluble antigen. Journal of Immunology, 155, 54275435.
  • Chan, V.W., Kothakota, S., Rohan, M.C., Panganiban-Lustan, L., Gardner, J.P., Wachowicz, M.S., Winter, J.A. & Williams, L.T. (1999) Secondary lymphoid-tissue chemokine (SLC) is chemotactic for mature dendritic cells. Blood, 93, 36103616.
  • Chen, S., Zani, C., Khouri, Y. & Marasco, W.A. (1995) Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Therapy, 2, 116123.
  • Chiriva-Internati, M., Liu, Y., Weidanz, J.A., Grizzi, F., You, H., Zhou, W., Bumm, K., Barlogie, B., Mehta, J.L. & Hermonat, P.L. (2003) Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood, 102, 31003107.
  • Coiffier, B., Haioun, C., Ketterer, N., Engert, A., Tilly, H., Ma, D., Johnson, P., Lister, A., Feuring-Buske, M., Radford, J.A., Capdeville, R., Diehl, V. & Reyes, F. (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood, 92, 19271932.
  • Cook, G. & Campbell, J.D. (1999) Immune regulation in multiple myeloma: the host-tumour conflict. Blood Reviews, 13, 151162.
  • Cook, G., Campbell, J.D., Carr, C.E., Boyd, K.S. & Franklin, I.M. (1999) Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. Journal of Leukocyte Biology, 66, 981988.
  • Corradini, P., Voena, C., Tarella, C., Astolfi, M., Ladetto, M., Palumbo, A., Van Lint, M., Bacigalupo, A., Santro, A., Musso, M., Majolino, I., Boccadoro, M. & Pileri, A. (1999) Molecular and clinical remission in multiple myeloma: role of autologous and allogeneic transplantation of haematopoietic cells. Journal of Clinical Oncology, 17, 208215.
  • Corral, L., Haslett, P., Muller, G., Chen, R., Wong, L., Ocampo, C., Patterson, R., Stirling, D. & Kaplan, G. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. Journal of Immunology, 163, 380.
  • Coscia, M., Mariani, S., Battaglio, S., Di Bello, C., Fiore, F., Foglietta, M., Pileri, A., Boccadoro, M. & Massaia, M. (2004) Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia, 18, 139145.
  • Crawley, C., Lalancette, M., Szydlo, R., Gilleece, M., Peggs, K., Mackinnon, S., Juliusson, G., Ahlberg, L., Nagler, A., Shimoni, A., Sureda, A., Boiron, J.-M., Einsele, H., Chopra, R., Carella, A., Cavenagh, J., Gratwohl, A., Garban, F., Zander, A., Bjorkstrand, B., Niederwieser, D., Gahrton, G. & Apperley, J.F. (2005) Outcomes for reduced intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the chronic leukemia working party of the EBMT. Blood, 105, 45324539.
  • Dabadghao, S., Bergenbrant, S., Anton, D., He, W., Holm, G. & Yi, Q. (1998) Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. British Journal of Haematology, 100, 647654.
  • Dauer, M., Obermaier, B., Herten, J., Haerle, C., Pohl, K., Rothenfusser, S., Schnurr, M., Endres, S. & Eigler, A. (2003) Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. Journal of Immunology, 170, 40694076.
  • De Vries, I.J., Krooshoop, D.J., Scharenborg, N.M., Lesterhuis, W.J., Diepstra, J.H., Van Muijen, G.N., Strijk, S.P., Ruers, T.J., Boerman, O.C., Oyen, W.J., Adema, G.J., Punt, C.J. & Figdor, C.G. (2003a) Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Research, 63, 1217.
  • De Vries, I.J., Lesterhuis, W.J., Scharenborg, N.M., Engelen, L.P., Ruiter, D.J., Gerritsen, M.J., Croockewit, S., Britten, C.M., Torensma, R., Adema, G.J., Figdor, C.G. & Punt, C.J. (2003b) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clinical Cancer Research, 9, 50915100.
  • Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C. & Bhardwaj, N. (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. Journal of Experimental Medicine, 193, 233238.
  • Dieu, M.C., Vanbervliet, B., Vicari, A., Bridon, J.M., Oldham, E., Ait-Yahia, S., Briere, F., Zlotnik, A., Lebecque, S. & Caux, C. (1998) Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. Journal of Experimental Medicine, 188, 373386.
  • Dimopoulos, M.A., Zervas, C., Zomas, A., Hamilos, G., Gika, D., Efstathiou, E., Panayiotidis, P., Vervessou, E., Anagnostopoulos, N. & Christakis, J. (2002) Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. Clinical Lymphoma, 3, 163166.
  • Dong, R., Cwynarski, K., Entwistle, A., Marelli-Berg, F., Dazzi, F., Simpson, E., Goldman, J.M., Melo, J.V., Lechler, R.I., Bellantuono, I., Ridley, A. & Lombardi, G. (2003) Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration. Blood, 101, 35603567.
  • Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Yang, J.C., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Sherry, R., Restifo, N.P., Hubicki, A.M., Robinson, M.R., Raffeld, M., Duray, P., Seipp, C.A., Rogers-Freezer, L., Morton, K.E., Mavroukakis, S.A., White, D.E. & Rosenberg, S.A. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298, 850854.
  • Dzionek, A., Fuchs, A., Schmidt, P., Cremer, S., Zysk, M., Miltenyi, S., Buck, D.W. & Schmitz, J. (2000) BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. Journal of Immunology, 165, 60376046.
  • EL-Sherbiny, Y.M., Davies, F.E., Cook, G., Johnson, R.J., Cullen, M.J., Sah, A., Rawstron, A.C., Richards, S.J. & Morgan, G.J. (2003) NK cell repertoire in myeloma and the impact of thalidomide. Blood, 102, abstract no. 1617.
  • Ellis J.H., Barber K.A., Tutt A, Hale C, Lewis A.P., Glennie M.J., Stevenson G.T., & Crowe J.S. (1995) Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. Journal of Immunology, 155, 925927.
  • Elrick, L.J., Jorgensen, H.G., Mountford, J.C. & Holyoake, T.L. (2005) Punish the parent not the progeny. Blood, 105, 18621866.
  • Evans, J.T., Cravens, P., Lipsky, P.E. & Garcia, J.V. (2000) Differentiation and expansion of lentivirus vector-marked dendritic cells derived from human CD34(+) cells. Human Gene Therapy, 11, 24832492.
  • Fearnley, D.B., McLellan, A.D., Mannering, S.I., Hock, B.D. & Hart, D.N. (1997) Isolation of human blood dendritic cells using the CMRF-44 monoclonal antibody: implications for studies on antigen-presenting cell function and immunotherapy. Blood, 89, 37083716.
  • Ferlazzo, G. & Munz, C. (2004) NK cell compartments and their activation by dendritic cells. Journal of Immunology, 172, 13331339.
  • Ferlazzo, G., Klein, J., Paliard, X., Wei, W.Z. & Galy, A. (2000) Dendritic cells generated from CD34+ progenitor cells with flt3 ligand, c-kit ligand, GM-CSF, IL-4, and TNF-alpha are functional antigen-presenting cells resembling mature monocyte-derived dendritic cells. Journal of Immunotherapy, 23, 4858.
  • Ferlazzo, G., Tsang, M.L., Moretta, L., Melioli, G., Steinman, R.M. & Munz, C. (2002) Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. Journal of Experimental Medicine, 195, 343351.
  • Frohn, C., Hoppner, M., Schlenke, P., Kirchner, H., Koritke, P. & Luhm, J. (2002) Anti-myeloma activity of natural killer lymphocytes. British Journal of Haematology, 119, 660664.
  • Gale, R.P., Horowitz, M.M. & Bortin, M.M. (1989) IBMTR analysis of bone marrow transplants in acute leukaemia. Advisory Committee of the International Bone Marrow Transplant Registry (IBMTR). Bone Marrow Transplantation, 4, 8384.
  • Galea-Lauri, J., Wells, J.W., Darling, D., Harrison, P. & Farzaneh, F. (2004) Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunology and Immunotherapy, 53, 963977.
  • Garban, F., Attal, M., Rossi, J.F., Payen, C., Fegueux, N., Sotto, J.J. & Intergroupe Francophone du M. (2001) Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. Leukemia, 15, 642646.
  • Gertz, M.A., Anagnostopoulos, A., Anderson, K., Branagan, A.R., Coleman, M., Frankel, S.R., Giralt, S., Levine, T., Munshi, N., Pestronk, A., Rajkumar, V. & Treon, S.P. (2003) Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Seminars in Oncology, 30, 121126.
  • Gimmi, C.D., Morrison, B.W., Mainprice, B.A., Gribben, J.G., Boussiotis, V.A., Freeman, G.J., Park, S.Y., Watanabe, M., Gong, J., Hayes, D.F., Kufe, D.W. & Nadler, L.M. (1996) Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nature Medicine, 2, 13671370.
  • Glenchur, H., Zinneman, H.H. & Hall, W.H. (1959) A review of fifty-one cases of multiple myeloma; emphasis on pneumonia and other infections as complications. American Medical Association Archives of Internal Medicine, 103, 173183.
  • Gluck, W.L., Hurst, D., Yuen, A., Levine, A.M., Dayton, M.A., Gockerman, J.P., Lucas, J., Denis-Mize, K., Tong, B., Navis, D., Difrancesco, A., Milan, S., Wilson, S.E. & Wolin, M. (2004) Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-Hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clinical Cancer Research, 10, 22532264.
  • Gong, J., Koido, S., Chen, D., Tanaka, Y., Huang, L., Avigan, D., Anderson, K., Ohno, T. & Kufe, D. (2002) Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood, 99, 25122517.
  • Gonzalez, M., San Miguel, J.F., Gascon, A., Moro, M.J., Hernandez, J.M., Ortega, F., Jimenez, R., Guerras, L., Romero, M., Casanova, F. et al. (1992) Increased expression of natural-killer-associated and activation antigens in multiple myeloma. American Journal of Hematology, 39, 8489.
  • Granucci, F., Vizzardelli, C., Pavelka, N., Feau, S., Persico, M., Virzi, E., Rescigno, M., Moro, G. & Ricciardi-Castagnoli, P. (2001) Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nature Immunology, 2, 882888 (comment).
  • Grimm, E.A., Mazumder, A., Zhang, H.Z. & Rosenberg, S.A. (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. Journal of Experimental Medicine, 155, 18231841.
  • Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J.L., Fraser, C.C., Cavazzana-Calvo, M. & Fischer, A. (2003a) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. New England Journal of Medicine, 348, 255256.
  • Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M.P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C.S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J.I., de Saint Basile, G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L.E., Wissler, M., Prinz, C., Rabbitts, T.H., Le Deist, F., Fischer, A. & Cavazzana-Calvo, M. (2003b) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415419.
  • Hao, S., Bi, X., Xu, S., Wei, Y., Wu, X., Guo, X., Carlsen, S. & Xiang, J. (2004) Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells. Experimental Oncology, 26, 300306.
  • Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M., Hoshino, K., Wagner, H., Takeda, K. & Akira, S. (2000) A toll-like receptor recognizes bacterial DNA. Nature, 408, 740745.
  • Hengel, H., Lindner, M., Wagner, H. & Heeg, K. (1987) Frequency of herpes simplex virus-specific murine cytotoxic T lymphocyte precursors in mitogen- and antigen-driven primary in vitro T cell responses. Journal of Immunology, 139, 41964202.
  • Howard, M., Spalk, E., Choudhury, K., Greten, T. & Schneck, J. (1999) MHC-based diagnostics and therapeutics- clinical applications for disease linked genes. Immunology Today, 20, 155198.
  • Hsu, F.J., Caspar, C.B., Czerwinski, D., Kwak, L.W., Liles, T.M., Syrengelas, A., Taidi-Laskowski, B. & Levy, R. (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma – long-term results of a clinical trial. Blood, 89, 31293135.
  • Huff, C.A. & Jones, R.J. (2002) Bone marrow transplantation for multiple myeloma: where we are today. Current Opinion in Oncology, 14, 147151.
  • Hughes, T.P., Economou, K., Mackinnon, S., Vlitos, M., Arthur, C.K., Guo, A.P., Rassool, F., Apperley, J.F., Hows, J. & Goldman, J.M. (1989) Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. British Journal of Haematology, 73, 462467.
  • Jones, R.J. (2003) Differentiation of cancer stem cells. Experimental Hematology, 31, S136.
  • Jones, E., Dahm-Vicker, M., Simon, A.K., Green, A., Powrie, F., Cerundolo, V. & Gallimore, A. (2002) Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice. Cancer Immunity, 2, 1.
  • Jonuleit, H., Schmitt, E., Steinbrink, K. & Enk, A.H. (2001a) Dendritic cells as a tool to induce anergic and regulatory T cells. Trends in Immunology, 22, 394400 (comment).
  • Jonuleit, H., Giesecke-Tuettenberg, A., Tuting, T., Thurner-Schuler, B., Stuge, T.B., Paragnik, L., Kandemir, A., Lee, P.P., Schuler, G., Knop, J. & Enk, A.H. (2001b) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. International Journal of Cancer, 93, 243251.
  • Kim, S.B., Baskar, S. & Kwak, L.W. (2003) In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells. Leukemia and Lymphoma, 44, 12011208.
  • King, C.A., Spellerberg, M.B., Zhu, D., Rice, J., Sahota, S.S., Thompsett, A.R., Hamblin, T.J., Radl, J. & Stevenson, F.K. (1998) DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nature Medicine, 4, 12811286.
  • Kiss, T.L., Spaner, D., Daly, A.S., Hasegawa, W.S., Lipton, J.H., Messner, H.A. & Chang, H. (2003) Complete remission of tumour with interleukin 2 therapy in a patient with non-Hodgkin's lymphoma post allogeneic bone marrow transplant associated with polyclonal T-cell bone marrow lymphocytosis. British Journal of Haematology, 120, 523525.
  • Kolb, H., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M. & Williams, W. (1990) Donor leukocyte transfusions for the treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood, 76, 24622465.
  • Kwak, L.W., Taub, D.D., Duffey, P.L., Bensinger, W.I., Bryant, E.M., Reynolds, C.W. & Longo, D.L. (1995) Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet, 345, 10161020.
  • Li, Y., Bendandi, M., Deng, Y., Dunbar, C., Munshi, N., Jagannath, S., Kwak, L.W. & Lyerly, H.K. (2000) Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood, 96, 28282833.
  • Lim, S.H. & Bailey-Wood, R. (1999) Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. International Journal of Cancer, 83, 215222.
  • Lim, S.H., Zhang, Y., Wang, Z., Varadarajan, R., Periman, P. & Esler, W.V. (2004) Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency. Blood, 103, 19711972.
  • Liso, A., Stockerl-Goldstein, K.E., Auffermann-Gretzinger, S., Benike, C.J., Reichardt, V., van Beckhoven, A., Rajapaksa, R., Engleman, E.G., Blume, K.G. & Levy, R. (2000) Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biology of Blood and Marrow Transplantation, 6, 621627.
  • Liu, Y.J., Kanzler, H., Soumelis, V. & Gilliet, M. (2001) Dendritic cell lineage, plasticity and cross-regulation. Nature Immunology, 2, 585589.
  • Ljunggren, H.G. & Karre, K. (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunology Today, 11, 237244 (comment).
  • Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., Thomas, L.L. & Verdonck, L.F. (1997) Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood, 90, 42064211.
  • Lokhorst, H.M., Schattenberg, A., Cornelissen, J.J., van Oers, M.H., Fibbe, W., Russell, I., Donk, N.W. & Verdonck, L.F. (2000) Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Journal of Clinical Oncology, 18, 30313037.
  • Lopez, J.A., Bioley, G., Turtle, C.J., Pinzon-Charry, A., Ho, C.S., Vuckovic, S., Crosbie, G., Gilleece, M., Jackson, D.C., Munster, D. & Hart, D.N. (2003) Single step enrichment of blood dendritic cells by positive immunoselection. Journal of Immunological Methods, 274, 4761.
  • Lotze, M.T., Grimm, E.A., Mazumder, A., Strausser, J.L. & Rosenberg, S.A. (1981) Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Research, 41, 44204425.
  • Lotze, M.T., Chang, A.E., Seipp, C.A., Simpson, C., Vetto, J.T. & Rosenberg, S.A. (1986) High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA, 256, 31173124.
  • Lowdell, M.W. & Koh, M.B. (2000) Immunotherapy of AML: future directions. Journal of Clinical Pathology, 53, 4954.
  • Lowdell, M.W., Ray, N., Craston, R., Corbett, T., Deane, M. & Prentice, H.G. (1997) The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemia. Bone Marrow Transplantation, 19, 891897.
  • Lowdell, M.W., Craston, R. & Prentice, H.G. (1999) Generation of autologous immunity to acute myeloid leukaemia and maintenance of complete remission following interferon-alpha treatment. Cytokines Cellular and Molecular Therapy, 5, 119121.
  • MacDonald, K.P., Munster, D.J., Clark, G.J., Dzionek, A., Schmitz, J. & Hart, D.N. (2002) Characterization of human blood dendritic cell subsets. Blood, 100, 45124520.
  • Maraskovsky, E., Brasel, K., Teepe, M., Roux, E., Lyman, S., Shortman, K. & McKenna, H. (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. Journal of Experimental Medicine, 184, 19531962.
  • Mariani, S., Coscia, M., Even, J., Peola, S., Foglietta, M., Boccadoro, M., Sbaiz, L., Restagno, G., Pileri, A. & Massaia, M. (2001) Severe and long-lasting disruption of T-cell receptor diversity in human myeloma after high-dose chemotherapy and autologous peripheral blood progenitor cell infusion. British Journal of Haematology, 113, 10511059.
  • Mathe, G., Amiel, J.L., Schwarzenberg, L., Cattan, A. & Schneider, M. (1965) Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Research, 25, 15251531.
  • Matsui, W., Huff, C.A., Wang, Q., Malehorn, M.T., Barber, J., Tanhehco, Y., Smith, B.D., Civin, C.I. & Jones, R.J. (2004) Characterization of clonogenic multiple myeloma cells. Blood, 103, 23322336.
  • Matzinger, P. (1998) An innate sense of danger. Seminars in Immunology, 10, 399415.
  • Matzinger, P. & Guerder, S. (1989) Does T-cell tolerance require a dedicated antigen-presenting cell? Nature, 338, 7476.
  • McCormack, M. & Rabbitts, T. (2004) Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combine immunodeficiency. New England Journal of Medicine, 350, 913922.
  • McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 28252833.
  • Mellor, A.L., Baban, B., Chandler, P., Marshall, B., Jhaver, K., Hansen, A., Koni, P.A., Iwashima, M. & Munn, D.H. (2003) Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. Journal of Immunology, 171, 16521655.
  • Miller, M.J., Safrina, O., Parker, I. & Cahalan, M.D. (2004) Imaging the single cell dynamics of CD4+ T cell activation by dendritic cells in lymph nodes. Journal of Experimental Medicine, 200, 847856.
  • Moretta, L., Ferlazzo, G., Mingari, M.C., Melioli, G. & Moretta, A. (2003) Human natural killer cell function and their interactions with dendritic cells. Vaccine, 21, S38S42.
  • Morse, M.A., Lyerly, H.K. & Li, Y. (1999) The role of IL-13 in the generation of dendritic cells in vitro. Journal of Immunotherapy, 22, 506513.
  • Morse, M.A., Nair, S., Fernandez-Casal, M., Deng, Y., St Peter, M., Williams, R., Hobeika, A., Mosca, P., Clay, T., Cumming, R.I., Fisher, E., Clavien, P., Proia, A.D., Niedzwiecki, D., Caron, D. & Lyerly, H.K. (2000) Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. Journal of Clinical Oncology, 18, 38833893 (comment).
  • Munn, D.H., Sharma, M.D., Lee, J.R., Jhaver, K.G., Johnson, T.S., Keskin, D.B., Marshall, B., Chandler, P., Antonia, S.J., Burgess, R., Slingluff, Jr, C.L. & Mellor, A.L. (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science, 297, 18671870.
  • Musto, P., Carella, Jr, A.M., Greco, M.M., Falcone, A., Sanpaolo, G., Bodenizza, C., Cascavilla, N., Melillo, L. & Carella, A.M. (2003) Short progression-free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation. British Journal of Haematology, 123, 746747 (comment).
  • Osterborg, A., Yi, Q., Henriksson, L., Fagerberg, J., Bergenbrant, S., Jeddi-Tehrani, M., Ruden, U., Lefvert, A.K., Holm, G. & Mellstedt, H. (1998) Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood, 91, 24592466.
  • Overwijk, W.W., Theoret, M.R., Finkelstein, S.E., Surman, D.R., de Jong, L.A., Vyth-Dreese, F.A., Dellemijn, T.A., Antony, P.A., Spiess, P.J., Palmer, D.C., Heimann, D.M., Klebanoff, C.A., Yu, Z., Hwang, L.N., Feigenbaum, L., Kruisbeek, A.M., Rosenberg, S.A. & Restifo, N.P. (2003) Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. Journal of Experimental Medicine, 198, 569580.
  • Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D.P. & Gabrilovich, D.I. (1998) Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. Journal of Immunology, 160, 12241232.
  • Perez-Simon, J.A., Martino, R., Alegre, A., Tomas, J.F., De Leon, A., Caballero, D., Sureda, A., Sierra, J. & San Miguel, J.F. (2003) Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. British Journal of Haematology, 121, 104108.
  • Perri, R.T., Hebbel, R.P. & Oken, M.M. (1981) Influence of treatment and response status on infection risk in multiple myeloma. American Journal of Medicine, 71, 935940.
  • Prabhala, R., Neri, P., Tassone, P., Shammas, M.A., Bae, J., Cumming, V.M., Allam, C.K., Daley, J.F., Desarneud, F., Chauhan, D., Blanchard, E., Anderson, K. & Munshi, N.C. (2004) Dysregulated CD4+ CD25+ T-regulatory cells and TLRs in myeloma. Blood, 104, abstract no. 2466.
  • Propato, A., Cutrona, G., Francavilla, V., Ulivi, M., Schiaffella, E., Landt, O., Dunbar, R., Cerundolo, V., Ferrarini, M. & Barnaba, V. (2001) Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nature Medicine, 7, 807813.
  • Qu, C., Edwards, E.W., Tacke, F., Angeli, V., Llodra, J., Sanchez-Schmitz, G., Garin, A., Haque, N.S., Peters, W., van Rooijen, N., Sanchez-Torres, C., Bromberg, J., Charo, I.F., Jung, S., Lira, S.A. & Randolph, G.J. (2004) Role of CCR8 and other chemokine pathways in the migration of monocyte-derived dendritic cells to lymph nodes. Journal of Experimental Medicine, 200, 12311241.
  • Raitakari, M., Brown, R.D., Gibson, J. & Joshua, D.E. (2003) T cells in myeloma. Hematological Oncology, 21, 3342.
  • Raje, N., Hideshima, T., Davies, F.E., Chauhan, D., Treon, S.P., Young, G., Tai, Y.T., Avigan, D., Gong, J., Schlossman, R.L., Richardson, P., Kufe, D.W. & Anderson, K.C. (2004) Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. British Journal of Haematology, 125, 343352.
  • Rasmussen, T., Hansson, L., Osterborg, A., Johnsen, H.E. & Mellstedt, H. (2003) Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood, 101, 46074610.
  • Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G.R., Tura, S., Baccarani, M. & Lemoli, R.M. (2002) Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood, 100, 230237.
  • Ravaud, A., Negrier, S., Cany, L., Merrouche, Y., Le Guillou, M., Blay, J.Y., Clavel, M., Gaston, R., Oskam, R. & Philip, T. (1994) Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. British Journal of Cancer, 69, 11111114.
  • Reichardt, V., Okada, C., Liso, A., Benike, C., Stockerl-Goldstein, K., Engleman, E., Blume, K. & Levy, R. (1999) Idiotype vaccination using dendritic cells afterautologous peripheral blood stem cell transplantation for multiple myeloma – a feasibility study. Blood, 93, 24112419.
  • Reichardt, V.L., Milazzo, C., Brugger, W., Einsele, H., Kanz, L. & Brossart, P. (2003) Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica, 88, 11391149.
  • Reid, C.D., Stackpoole, A., Meager, A. & Tikerpae, J. (1992) Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow. Journal of Immunology, 149, 26812688.
  • Rew, S.B., Lopes, L., Koishihara, Y., Kosaka, M., Ozaki, S., Peggs, K., Chain, B. & Yong, K.L. (2003) Potent anti-tumour cytotoxic T lymphocytes directed against the myeloma antigen HM1.24. Blood, 102, abstract no. 380.
  • van Rhee, F., Szmania, S.M., Zhan, F., Gupta, S.K., Pomtree, M., Lin, P., Batchu, R.B., Moreno, A., Spagnoli, G., Shaughnessy, J. & Tricot, G.J. (2005) NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood, 105, 39343944.
  • Rice, A. & Hart, D. (2002) Technology evaluation: APC-80200, Dendreon. Current Opinion in Molecular Therapeutics, 4, 523527.
  • Ridgway, D. (2003) The first 1000 dendritic cell vaccinees. Cancer Investigation, 21, 873886.
  • Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B., Niederwieser, D. & Schuler, G. (1996) Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. Journal of Immunological Methods, 196, 137151.
  • Rosenberg, S.A. & Lotze, M.T. (1986) Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annual Review of Immunology, 4, 681709.
  • Rosenberg, S.A., Lotze, M.T., Muul, L.M., Leitman, S., Chang, A.E., Ettinghausen, S.E., Matory, Y.L., Skibber, J.M., Shiloni, E., Vetto, J.T. Seipp C.A., Simpson C. & Reichert C.M. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New England Journal of Medicine, 313, 14851492.
  • Rosenberg, S.A., Lotze, M.T., Muul, L.M., Chang, A.E., Avis, F.P., Leitman, S., Linehan, W.M., Robertson, C.N., Lee, R.E., Rubin, J.T. Seipp C.A. Simpson C.G. & White D.E. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New England Journal of Medicine, 316, 889897.
  • Rosenberg, S.A., Yannelli, J.R., Yang, J.C., Topalian, S.L., Schwartzentruber, D.J., Weber, J.S., Parkinson, D.R., Seipp, C.A., Einhorn, J.H. & White, D.E. (1994) Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. Journal of the National Cancer Institute, 86, 11591166 (see comment).
  • Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. & Toda, M. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology, 155, 11511164.
  • Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M. & Takahashi, T. (2001) Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunological Reviews, 182, 1832.
  • Salama, M., Nevill, T., Marcellus, D., Parker, P., Johnson, M., Kirk, A., Porter, D., Giralt, S., Levine, J.E., Drobyski, W., Barrett, A.J., Horowitz, M. & Collins, R.H. (2000) Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplantation, 26, 11791184.
  • Santiago-Schwarz, F., Belilos, E., Diamond, B. & Carsons, S.E. (1992) TNF in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. Journal of Leukocyte Biology, 52, 274281.
  • Savelyeva, N., Munday, R., Spellerberg, M.B., Lomonossoff, G.P. & Stevenson, F.K. (2001) Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nature Biotechnology, 19, 760764,.
  • Shigematsu, H., Iwagaki, H., Mizuno, S. & Akashi, K. (2003) The majority of plasmacytoid dendritic cells originate from myeloid progenitors in murine hematopoiesis. Experimental Hematology, 31, S195.
  • Shimizu, K., Fields, R.C., Giedlin, M. & Mule, J.J. (1999) Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proceedings of the National Academy of Sciences of the United States of America, 96, 22682273.
  • Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 15651571.
  • Singhal, S., Safdar, A., Chiang, K.Y., Godder, K., van Rhee, F., Garner, F., Foster, B., Dubovsky, D., Henslee-Downey, P.J. & Mehta, J. (2000) Non-myeloablative allogeneic transplantation (‘microallograft’) for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis. Bone Marrow Transplantation, 26, 12311233.
  • Slavin, S., Naparstek, E., Nagler, A., Ackerstein, A., Samuel, S., Kapelushnik, J., Brautbar, C. & Or, R. (1996) Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood, 87, 21952204.
  • Spellerberg, M.B., Zhu, D., Thompsett, A., King, C.A., Hamblin, T.J. & Stevenson, F.K. (1997) DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. Journal of Immunology, 159, 18851892.
  • Steinman, R.M. & Cohn, Z.A. (1973) Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology. Journal of Experimental Medicine, 137, 11421162.
  • Steinman, R.M. & Cohn, Z.A. (1974) Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro. Journal of Experimental Medicine, 139, 380397.
  • Steinman, R.M., Lustig, D.S. & Cohn, Z.A. (1974) Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo. Journal of Experimental Medicine, 139, 14311445.
  • Steinman, R.M., Adams, J.C. & Cohn, Z.A. (1975) Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. Journal of Experimental Medicine, 141, 804820.
  • Stevenson, F.K. (2003) DNA vaccination: from the laboratory to the clinic. Hematology Journal, 4, S83.
  • Stevenson, F.K., Ottensmeier, C.H., Johnson, P., Zhu, D., Buchan, S.L., McCann, K.J., Roddick, J.S., King, A.T., McNicholl, F., Savelyeva, N. & Rice, J. (2004) DNA vaccines to attack cancer. Proceedings of the National Academy of Science of the United States of America, 101(Suppl. 2), 1464614652.
  • Stritzke, J., Zunkel, T., Steinmann, J., Schmitz, N., Uharek, L. & Zeis, M. (2003) Therapeutic effects of idiotype vaccination can be enhanced by the combination of granulocyte-macrophage colony-stimulating factor and interleukin 2 in a myeloma model. British Journal of Haematology, 120, 2735.
  • Strunk, D., Rappersberger, K., Egger, C., Strobl, H., Kromer, E., Elbe, A., Maurer, D. & Stingl, G. (1996) Generation of human dendritic cells/Langerhans cells from circulating CD34+ hematopoietic progenitor cells. Blood, 87, 12921302.
  • Sutmuller, R.P., van Duivenvoorde, L.M., van Elsas, A., Schumacher, T.N., Wildenberg, M.E., Allison, J.P., Toes, R.E., Offringa, R. & Melief, C.J. (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. Journal of Experimental Medicine, 194, 823832.
  • Svensson, M., Stockinger, B. & Wick, M.J. (1997) Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. Journal of Immunology, 158, 42294236.
  • Sze, D.M., Brown, R.D., Yang, S., Ho, J.P., Gibson, J., Fazekas de St Groth, B., Basten, A. & Joshua, D.E. (2003) Clonally expanded T cells in myeloma with a late memory/effector phenotype are associated with improved survival. Blood, 102, abstract no. 3451.
  • Szmania, S.M., Rosen, N.A., Freeman, J., Batchu, R.B., Barlogie, B., Tricot, G., Cottler-Fox, M.H., Yi, Q. & Van Rhee, F. (2003) Cryopreserved tumor protein loaded dendritic cell vaccines induce potent immune responses in patient with poor prognosis multiple myeloma. Blood, 102, abstract no. 1652.
  • Tarte, K., Lu, Z.Y., Fiol, G., Legouffe, E., Rossi, J.F. & Klein, B. (1997) Generation of virtually pure and potentially proliferating dendritic cells from non-CD34 apheresis cells from patients with multiple myeloma. Blood, 90, 34823495.
  • Tarte, K., Fiol, G., Rossi, J.F. & Klein, B. (2000) Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia, 14, 21822192.
  • Thurnher, M., Papesh, C., Ramoner, R., Gastl, G., Bock, G., Radmayr, C., Klocker, H. & Bartsch, G. (1997) In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Experimental Hematology, 25, 232237.
  • Titzer, S., Christensen, O., Manzke, O., Tesch, H., Wolf, J., Emmerich, B., Carsten, C., Diehl, V. & Bohlen, H. (2000) Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. British Journal of Haematology, 108, 805816.
  • Treon, S.P., Maimonis, P., Chauhan, D. & Anderson, K.C. (1998) Soluble Muc-1 is elevated in multiple myeloma (MM) bone marrow (BM) plasma and inhibits T cell proliferation. Blood, 92, 411a.
  • Treon, S.P., Agus, T.B., Link, B., Rodrigues, G., Molina, A., Lacy, M.Q., Fisher, D.C., Emmanouilides, C., Richards, A.I., Clark, B., Lucas, M.S., Schlossman, R., Schenkein, D., Lin, B., Kimby, E., Anderson, K.C. & Byrd, J.C. (2001) CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. Journal of Immunotherapy, 24, 272279.
  • Tricot, G., Vesole, D., Jagannath S, Hilton J, Munshi N, & Barlogie B. (1996) Graft-versus-myeloma effect: proof of principle. Blood, 87, 11961199.
  • Verdonck, L.F., Petersen, E.J., Lokhorst, H.M., Nieuwenhuis, H.K., Dekker, A.W., Tilanus, M.G. & de Weger, R.A. (1998) Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplantation, 22, 10571063.
  • Vij, R., Borrello, I., Martin, T., Vescio, R., Siegel, D., Bashey, A., Di Persio, J.F., Berenson, J., Ferrand, C., Janmohamed, F., Yuan, V., Bouchard, L., Berenson, R.J., Bonyhadi, M. & Frohlich, W. (2003) A phase I/II study of Xcellerated T cells after autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Blood, 102, abstract no. 139.
  • Vilches, C. & Parham, P. (2002) KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annual Review of Immunology, 20, 217251.
  • Villunger, A., Egle, A., Marschitz, I., Kos, M., Bock, G., Ludwig, H., Geley, S., Kofler, R. & Greil, R. (1997) Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance. Blood, 90, 1220.
  • Wen, Y.J., Barlogie, B. & Yi, Q. (2001) Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells. Blood, 97, 17501755.
  • Wen, Y.J., Min, R., Tricot, G., Barlogie, B. & Yi, Q. (2002) Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood, 99, 32803285.
  • Williams, N.S., Moore, T.A., Schatzle, J.D., Puzanov, I.J., Sivakumar, P.V., Zlotnik, A., Bennett, M. & Kumar, V. (1997) Generation of lytic natural killer 1.1+, Ly-49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates. Journal of Experimental Medicine, 186, 16091614.
  • Wood, K.J. & Sakaguchi, S. (2003) Regulatory T cells in transplantation tolerance. Nature Reviews. Immunology, 3, 199210.
  • Xu, S., Koski, G.K., Faries, M., Bedrosian, I., Mick, R., Maeurer, M., Cheever, M.A., Cohen, P.A. & Czerniecki, B.J. (2003) Rapid high efficiency sensitization of CD8+ T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism. Journal of Immunology, 171, 22512261.
  • Yang, J.C., Haworth, L., Sherry, R.M., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Steinberg, S.M., Chen, H.X. & Rosenberg, S.A. (2003a) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. New England Journal of Medicine, 349, 427434.
  • Yang, J.C., Sherry, R.M., Steinberg, S.M., Topalian, S.L., Schwartzentruber, D.J., Hwu, P., Seipp, C.A., Rogers-Freezer, L., Morton, K.E., White, D.E., Liewehr, D.J., Merino, M.J. & Rosenberg, S.A. (2003b) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. Journal of Clinical Oncology, 21, 31273132.
  • Yi, Q., Osterborg, A., Bergenbrant, S., Mellstedt, H., Holm, G. & Lefvert, A.K. (1995) Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood, 86, 30433049.
  • Yi, Q., Desikan, R., Barlogie, B. & Munshi, N. (2002) Optimizing dendritic cell-based immunotherapy in multiple myeloma. British Journal of Haematology, 117, 297305.
  • Yi, Q., Freeman, M.E., Szmania, S., Rosen, N., Cottler-Fox, M., Barlogie, B., Tricot, G. & Van Rhee, F. (2003) Intranodal vaccination with idiotype-pulsed dendritic cells induces potent and long-lasting cellular and humoral immune responses in myeloma patients. Blood, 102, abstract no. 5277.
  • Yiwen, L., Bendandi, M., Deng, Y., Dunbar, C., Munshi, N., Jagannath, S., Kwak, L. & Lyerly, H. (2000) Tumour-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells. Blood, 96, 28282833.
  • Zeis, M., Frenzke, H., Uharek, L., Glass, B., Schmitz, N., M., Kronke & Steinmann, J. (1998) Dendritic cells pulsed with idiotypic determinants induce anti-tumour immunity against established multiple myeloma. Blood, 92, 4229.
  • Zeis, M., Zunkel, T., Steinmann, J., Schmitz, N. & Uharek, L. (2002) Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma. British Journal of Haematology, 117, 93102.
  • Zheng, C., Ostad, M., Andersson, M., Celsing, F., Holm, G. & Sundblad, A. (2002) Natural cytotoxicity to autologous antigen-pulsed dendritic cells in multiple myeloma. British Journal of Haematology, 118, 778785.
  • Zhu, K., Shen, Q., Ulrich, M. & Zheng, M. (2000) Human monocyte-derived dendritic cells expressing both chemotactic cytokines IL-8, MCP-1, RANTES and their receptors, and their selective migration to these chemokines. Chinese Medical Journal, 113, 11241128.
  • Zinneman, H.H. & Hall, W.H. (1954) Recurrent pneumonia in multiple myeloma and some observations on immunologic response. Annals of Internal Medicine, 41, 11521163.
  • Zinzani, P.L., Pulsoni, A., Perrotti, A., Soverini, S., Zaja, F., De Renzo, A., Storti, S., Lauta, V.M., Guardigni, L., Gentilini, P., Tucci, A., Molinari, A.L., Gobbi, M., Falini, B., Fattori, P.P., Ciccone, F., Alinari, L., Martelli, M., Pileri, S., Tura, S. & Baccarani, M. (2004) Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without Rituximab as front-line treatment for patients with follicular lymphoma. Journal of Clinical Oncology, 22, 26542661.